stocknews8h
3 Pharmaceutical Stocks With Blockbuster Drug Potential
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
BioPharma Dive12h
Sanofi, Teva add to case for new bowel disease drug
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
AFP16h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...
Dealbreaker on MSN9h
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.
Mirum Pharmaceuticals announces FDA approval for Ctexli tablets
Mirum Pharmaceuticals (MIRM) announced that the FDA has approved Ctexli tablets, a bile acid, for the treatment of adults with cerebrotendinous ...
BioPharma Dive11h
Mirum drug for rare genetic disease gains FDA approval
Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...
STAT13h
FDA approves first drug for rare lipid storage disease
An approval for the first drug for a rare lipid storage disease, some FDA workers rehired, and other biotech news of the day ...
Deal pays off for drugmaker with approval for rare cholesterol-related disease treatment
A young Peninsula drugmaker won regulatory approval Friday for a rare-disease drug picked up in a deal two years ago.